Radioresistant malignant myoepithelioma of the breast with high level of ataxia telangiectasia mutated protein.

Abstract

Malignant myoepithelioma of the breast (MMB) is a rare and often aggressive disease with poor prognosis. Little is known regarding its optimal treatment and progression. We describe the clinical history of a woman following excision of a benign adenomyoepithelioma which recurred years later as a radioresistant malignant myoepithelioma with high levels of ataxia telangiectasia mutated protein and mutant p53 (Cys135Phe). MMB requires close follow-up and aggressive treatment. If adjuvant radiotherapy is adopted to improve local control, minimal postoperative delay and higher doses than for standard post-mastectomy radiation are recommended.

• Authors: Z M Fang, R V Tse, V M Marjoniemi, S Kozlov, M F Lavin, H Chen, J H Kearsley, P H Graham, R A Clarke
• Journal: Journal of medical imaging and radiation oncology (J Med Imaging Radiat Oncol) Vol. 53 Issue 2 Pg. 234-9 (Apr 2009) ISSN: 1754-9485 [Electronic] Australia
• PMID: 19527373 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cell Cycle Proteins
• DNA-Binding Proteins
• Tumor Suppressor Proteins
• ATM protein, human
• Ataxia Telangiectasia Mutated Proteins
• Protein Serine-Threonine Kinases

Topics

• Ataxia Telangiectasia Mutated Proteins
• Breast Neoplasms (metabolism, radiotherapy)
• Cell Cycle Proteins (analysis)
• DNA-Binding Proteins (analysis)
• Female
• Humans
• Middle Aged
• Myoepithelioma (radiotherapy)
• Protein Serine-Threonine Kinases (analysis)
• Treatment Failure
• Tumor Suppressor Proteins (analysis)